Urine neutrophil gelatinase-associated lipocalin to predict renal response after induction therapy in active lupus nephritis
Background Tubulointerstitial injury is important to predict the progression of lupus nephritis (LN). Urine neutrophil gelatinase-associated lipocalin (NGAL) has been reported to detect worsening LN disease activity. Thus, urine NGAL may predict renal outcomes among lupus patients. Methods We conduc...
Saved in:
| Published in | BMC nephrology Vol. 18; no. 1; pp. 263 - 8 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
04.08.2017
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1471-2369 1471-2369 |
| DOI | 10.1186/s12882-017-0678-3 |
Cover
| Abstract | Background
Tubulointerstitial injury is important to predict the progression of lupus nephritis (LN). Urine neutrophil gelatinase-associated lipocalin (NGAL) has been reported to detect worsening LN disease activity. Thus, urine NGAL may predict renal outcomes among lupus patients.
Methods
We conducted a prospective multi-center study among active LN patients with biopsy-proven. All patients provided urine samples for NGAL measurement by ELISA collected from all patients at baseline and at 6-month follow-up after induction therapy.
Results
In all, 68 active LN patients were enrolled (mean age 31.7 ± 10.0 years, median UPCR 4.8 g/g creatinine level with interquartile range (IQR) 2.5 to 6.9 and mean estimated glomerular filtration rate (GFR) 89.6 ± 33.7 mL/min/1.73 m
2
). At baseline measurement, median urinary NGAL in complete response, partial response and nonresponse groups was 10.86 (IQR; 6.16, 22.4), 19.91 (IQR; 9.05, 41.91) and 65.5 (IQR; 18.3, 103) ng/mL, respectively (
p
= 0.006). Urinary NGAL (ng/mL) correlated positively with proteinuria and blood pressure, and correlated negatively with serum complement C3 level and estimated GFR. Based on ROC analysis, urinary NGAL (AUC; 0.724, 95%CI 0.491–0.957) outperformed conventional biomarkers (serum creatinine, urine protein, and GFR) in differentiating complete and partial response groups from the nonresponse group. The urine NGAL cut-off value in the ROC curve, 28.08 ng/mL, discriminated nonresponse with 72.7% sensitivity and 68.4% specificity.
Conclusion
Urine NGAL at baseline performed better than conventional markers in predicting a clinical response to treatment of active LN except serum complement C3 level. It may have the potential to predict poor response after induction therapy. |
|---|---|
| AbstractList | Tubulointerstitial injury is important to predict the progression of lupus nephritis (LN). Urine neutrophil gelatinase-associated lipocalin (NGAL) has been reported to detect worsening LN disease activity. Thus, urine NGAL may predict renal outcomes among lupus patients.
We conducted a prospective multi-center study among active LN patients with biopsy-proven. All patients provided urine samples for NGAL measurement by ELISA collected from all patients at baseline and at 6-month follow-up after induction therapy.
In all, 68 active LN patients were enrolled (mean age 31.7 ± 10.0 years, median UPCR 4.8 g/g creatinine level with interquartile range (IQR) 2.5 to 6.9 and mean estimated glomerular filtration rate (GFR) 89.6 ± 33.7 mL/min/1.73 m
). At baseline measurement, median urinary NGAL in complete response, partial response and nonresponse groups was 10.86 (IQR; 6.16, 22.4), 19.91 (IQR; 9.05, 41.91) and 65.5 (IQR; 18.3, 103) ng/mL, respectively (p = 0.006). Urinary NGAL (ng/mL) correlated positively with proteinuria and blood pressure, and correlated negatively with serum complement C3 level and estimated GFR. Based on ROC analysis, urinary NGAL (AUC; 0.724, 95%CI 0.491-0.957) outperformed conventional biomarkers (serum creatinine, urine protein, and GFR) in differentiating complete and partial response groups from the nonresponse group. The urine NGAL cut-off value in the ROC curve, 28.08 ng/mL, discriminated nonresponse with 72.7% sensitivity and 68.4% specificity.
Urine NGAL at baseline performed better than conventional markers in predicting a clinical response to treatment of active LN except serum complement C3 level. It may have the potential to predict poor response after induction therapy. Background Tubulointerstitial injury is important to predict the progression of lupus nephritis (LN). Urine neutrophil gelatinase-associated lipocalin (NGAL) has been reported to detect worsening LN disease activity. Thus, urine NGAL may predict renal outcomes among lupus patients. Methods We conducted a prospective multi-center study among active LN patients with biopsy-proven. All patients provided urine samples for NGAL measurement by ELISA collected from all patients at baseline and at 6-month follow-up after induction therapy. Results In all, 68 active LN patients were enrolled (mean age 31.7 ± 10.0 years, median UPCR 4.8 g/g creatinine level with interquartile range (IQR) 2.5 to 6.9 and mean estimated glomerular filtration rate (GFR) 89.6 ± 33.7 mL/min/1.73 m 2 ). At baseline measurement, median urinary NGAL in complete response, partial response and nonresponse groups was 10.86 (IQR; 6.16, 22.4), 19.91 (IQR; 9.05, 41.91) and 65.5 (IQR; 18.3, 103) ng/mL, respectively ( p = 0.006). Urinary NGAL (ng/mL) correlated positively with proteinuria and blood pressure, and correlated negatively with serum complement C3 level and estimated GFR. Based on ROC analysis, urinary NGAL (AUC; 0.724, 95%CI 0.491–0.957) outperformed conventional biomarkers (serum creatinine, urine protein, and GFR) in differentiating complete and partial response groups from the nonresponse group. The urine NGAL cut-off value in the ROC curve, 28.08 ng/mL, discriminated nonresponse with 72.7% sensitivity and 68.4% specificity. Conclusion Urine NGAL at baseline performed better than conventional markers in predicting a clinical response to treatment of active LN except serum complement C3 level. It may have the potential to predict poor response after induction therapy. Tubulointerstitial injury is important to predict the progression of lupus nephritis (LN). Urine neutrophil gelatinase-associated lipocalin (NGAL) has been reported to detect worsening LN disease activity. Thus, urine NGAL may predict renal outcomes among lupus patients. We conducted a prospective multi-center study among active LN patients with biopsy-proven. All patients provided urine samples for NGAL measurement by ELISA collected from all patients at baseline and at 6-month follow-up after induction therapy. In all, 68 active LN patients were enrolled (mean age 31.7 [+ or -] 10.0 years, median UPCR 4.8 g/g creatinine level with interquartile range (IQR) 2.5 to 6.9 and mean estimated glomerular filtration rate (GFR) 89.6 [+ or -] 33.7 mL/min/1.73 m.sup.2). At baseline measurement, median urinary NGAL in complete response, partial response and nonresponse groups was 10.86 (IQR; 6.16, 22.4), 19.91 (IQR; 9.05, 41.91) and 65.5 (IQR; 18.3, 103) ng/mL, respectively (p = 0.006). Urinary NGAL (ng/mL) correlated positively with proteinuria and blood pressure, and correlated negatively with serum complement C3 level and estimated GFR. Based on ROC analysis, urinary NGAL (AUC; 0.724, 95%CI 0.491-0.957) outperformed conventional biomarkers (serum creatinine, urine protein, and GFR) in differentiating complete and partial response groups from the nonresponse group. The urine NGAL cut-off value in the ROC curve, 28.08 ng/mL, discriminated nonresponse with 72.7% sensitivity and 68.4% specificity. Urine NGAL at baseline performed better than conventional markers in predicting a clinical response to treatment of active LN except serum complement C3 level. It may have the potential to predict poor response after induction therapy. Abstract Background Tubulointerstitial injury is important to predict the progression of lupus nephritis (LN). Urine neutrophil gelatinase-associated lipocalin (NGAL) has been reported to detect worsening LN disease activity. Thus, urine NGAL may predict renal outcomes among lupus patients. Methods We conducted a prospective multi-center study among active LN patients with biopsy-proven. All patients provided urine samples for NGAL measurement by ELISA collected from all patients at baseline and at 6-month follow-up after induction therapy. Results In all, 68 active LN patients were enrolled (mean age 31.7 ± 10.0 years, median UPCR 4.8 g/g creatinine level with interquartile range (IQR) 2.5 to 6.9 and mean estimated glomerular filtration rate (GFR) 89.6 ± 33.7 mL/min/1.73 m2). At baseline measurement, median urinary NGAL in complete response, partial response and nonresponse groups was 10.86 (IQR; 6.16, 22.4), 19.91 (IQR; 9.05, 41.91) and 65.5 (IQR; 18.3, 103) ng/mL, respectively (p = 0.006). Urinary NGAL (ng/mL) correlated positively with proteinuria and blood pressure, and correlated negatively with serum complement C3 level and estimated GFR. Based on ROC analysis, urinary NGAL (AUC; 0.724, 95%CI 0.491–0.957) outperformed conventional biomarkers (serum creatinine, urine protein, and GFR) in differentiating complete and partial response groups from the nonresponse group. The urine NGAL cut-off value in the ROC curve, 28.08 ng/mL, discriminated nonresponse with 72.7% sensitivity and 68.4% specificity. Conclusion Urine NGAL at baseline performed better than conventional markers in predicting a clinical response to treatment of active LN except serum complement C3 level. It may have the potential to predict poor response after induction therapy. Background Tubulointerstitial injury is important to predict the progression of lupus nephritis (LN). Urine neutrophil gelatinase-associated lipocalin (NGAL) has been reported to detect worsening LN disease activity. Thus, urine NGAL may predict renal outcomes among lupus patients. Methods We conducted a prospective multi-center study among active LN patients with biopsy-proven. All patients provided urine samples for NGAL measurement by ELISA collected from all patients at baseline and at 6-month follow-up after induction therapy. Results In all, 68 active LN patients were enrolled (mean age 31.7 ± 10.0 years, median UPCR 4.8 g/g creatinine level with interquartile range (IQR) 2.5 to 6.9 and mean estimated glomerular filtration rate (GFR) 89.6 ± 33.7 mL/min/1.73 m2). At baseline measurement, median urinary NGAL in complete response, partial response and nonresponse groups was 10.86 (IQR; 6.16, 22.4), 19.91 (IQR; 9.05, 41.91) and 65.5 (IQR; 18.3, 103) ng/mL, respectively (p = 0.006). Urinary NGAL (ng/mL) correlated positively with proteinuria and blood pressure, and correlated negatively with serum complement C3 level and estimated GFR. Based on ROC analysis, urinary NGAL (AUC; 0.724, 95%CI 0.491-0.957) outperformed conventional biomarkers (serum creatinine, urine protein, and GFR) in differentiating complete and partial response groups from the nonresponse group. The urine NGAL cut-off value in the ROC curve, 28.08 ng/mL, discriminated nonresponse with 72.7% sensitivity and 68.4% specificity. Conclusion Urine NGAL at baseline performed better than conventional markers in predicting a clinical response to treatment of active LN except serum complement C3 level. It may have the potential to predict poor response after induction therapy. Tubulointerstitial injury is important to predict the progression of lupus nephritis (LN). Urine neutrophil gelatinase-associated lipocalin (NGAL) has been reported to detect worsening LN disease activity. Thus, urine NGAL may predict renal outcomes among lupus patients.BACKGROUNDTubulointerstitial injury is important to predict the progression of lupus nephritis (LN). Urine neutrophil gelatinase-associated lipocalin (NGAL) has been reported to detect worsening LN disease activity. Thus, urine NGAL may predict renal outcomes among lupus patients.We conducted a prospective multi-center study among active LN patients with biopsy-proven. All patients provided urine samples for NGAL measurement by ELISA collected from all patients at baseline and at 6-month follow-up after induction therapy.METHODSWe conducted a prospective multi-center study among active LN patients with biopsy-proven. All patients provided urine samples for NGAL measurement by ELISA collected from all patients at baseline and at 6-month follow-up after induction therapy.In all, 68 active LN patients were enrolled (mean age 31.7 ± 10.0 years, median UPCR 4.8 g/g creatinine level with interquartile range (IQR) 2.5 to 6.9 and mean estimated glomerular filtration rate (GFR) 89.6 ± 33.7 mL/min/1.73 m2). At baseline measurement, median urinary NGAL in complete response, partial response and nonresponse groups was 10.86 (IQR; 6.16, 22.4), 19.91 (IQR; 9.05, 41.91) and 65.5 (IQR; 18.3, 103) ng/mL, respectively (p = 0.006). Urinary NGAL (ng/mL) correlated positively with proteinuria and blood pressure, and correlated negatively with serum complement C3 level and estimated GFR. Based on ROC analysis, urinary NGAL (AUC; 0.724, 95%CI 0.491-0.957) outperformed conventional biomarkers (serum creatinine, urine protein, and GFR) in differentiating complete and partial response groups from the nonresponse group. The urine NGAL cut-off value in the ROC curve, 28.08 ng/mL, discriminated nonresponse with 72.7% sensitivity and 68.4% specificity.RESULTSIn all, 68 active LN patients were enrolled (mean age 31.7 ± 10.0 years, median UPCR 4.8 g/g creatinine level with interquartile range (IQR) 2.5 to 6.9 and mean estimated glomerular filtration rate (GFR) 89.6 ± 33.7 mL/min/1.73 m2). At baseline measurement, median urinary NGAL in complete response, partial response and nonresponse groups was 10.86 (IQR; 6.16, 22.4), 19.91 (IQR; 9.05, 41.91) and 65.5 (IQR; 18.3, 103) ng/mL, respectively (p = 0.006). Urinary NGAL (ng/mL) correlated positively with proteinuria and blood pressure, and correlated negatively with serum complement C3 level and estimated GFR. Based on ROC analysis, urinary NGAL (AUC; 0.724, 95%CI 0.491-0.957) outperformed conventional biomarkers (serum creatinine, urine protein, and GFR) in differentiating complete and partial response groups from the nonresponse group. The urine NGAL cut-off value in the ROC curve, 28.08 ng/mL, discriminated nonresponse with 72.7% sensitivity and 68.4% specificity.Urine NGAL at baseline performed better than conventional markers in predicting a clinical response to treatment of active LN except serum complement C3 level. It may have the potential to predict poor response after induction therapy.CONCLUSIONUrine NGAL at baseline performed better than conventional markers in predicting a clinical response to treatment of active LN except serum complement C3 level. It may have the potential to predict poor response after induction therapy. Background Tubulointerstitial injury is important to predict the progression of lupus nephritis (LN). Urine neutrophil gelatinase-associated lipocalin (NGAL) has been reported to detect worsening LN disease activity. Thus, urine NGAL may predict renal outcomes among lupus patients. Methods We conducted a prospective multi-center study among active LN patients with biopsy-proven. All patients provided urine samples for NGAL measurement by ELISA collected from all patients at baseline and at 6-month follow-up after induction therapy. Results In all, 68 active LN patients were enrolled (mean age 31.7 [+ or -] 10.0 years, median UPCR 4.8 g/g creatinine level with interquartile range (IQR) 2.5 to 6.9 and mean estimated glomerular filtration rate (GFR) 89.6 [+ or -] 33.7 mL/min/1.73 m.sup.2). At baseline measurement, median urinary NGAL in complete response, partial response and nonresponse groups was 10.86 (IQR; 6.16, 22.4), 19.91 (IQR; 9.05, 41.91) and 65.5 (IQR; 18.3, 103) ng/mL, respectively (p = 0.006). Urinary NGAL (ng/mL) correlated positively with proteinuria and blood pressure, and correlated negatively with serum complement C3 level and estimated GFR. Based on ROC analysis, urinary NGAL (AUC; 0.724, 95%CI 0.491-0.957) outperformed conventional biomarkers (serum creatinine, urine protein, and GFR) in differentiating complete and partial response groups from the nonresponse group. The urine NGAL cut-off value in the ROC curve, 28.08 ng/mL, discriminated nonresponse with 72.7% sensitivity and 68.4% specificity. Conclusion Urine NGAL at baseline performed better than conventional markers in predicting a clinical response to treatment of active LN except serum complement C3 level. It may have the potential to predict poor response after induction therapy. Keywords: Neutrophil gelatinase-associated lipocalin (NGAL), systemic lupus erythematosus (SLE), lupus nephritis (LN), ROC curve |
| ArticleNumber | 263 |
| Audience | Academic |
| Author | Kitiyakara, Chagriya Supasyndh, Ouppatham Leelahavanichkul, Asada Satirapoj, Bancha Avihingsanon, Yingyos |
| Author_xml | – sequence: 1 givenname: Bancha surname: Satirapoj fullname: Satirapoj, Bancha email: satirapoj@yahoo.com organization: Division of Nephrology, Department of Medicine, Phramongkutklao Hospital and College of Medicine – sequence: 2 givenname: Chagriya surname: Kitiyakara fullname: Kitiyakara, Chagriya organization: Division of Nephrology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University – sequence: 3 givenname: Asada surname: Leelahavanichkul fullname: Leelahavanichkul, Asada organization: Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University – sequence: 4 givenname: Yingyos surname: Avihingsanon fullname: Avihingsanon, Yingyos organization: Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University – sequence: 5 givenname: Ouppatham surname: Supasyndh fullname: Supasyndh, Ouppatham organization: Division of Nephrology, Department of Medicine, Phramongkutklao Hospital and College of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28778196$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktr3DAUhU1JaR7tD-imGLrpxqlkyXpsCiH0EQh006yFLF_NKGgkV5IDgf74ajpJOxPaYpDF1Tnf5UrntDkKMUDTvMboHGPB3mfcC9F3CPMOMS468qw5wZTjridMHu3tj5vTnG9RFQqKXjTHveBcYMlOmh83yQVoAywlxXntfLsCr4sLOkOnc47G6QJT690cjfYutCW2c4LJmdImCNrXNc8xZGi1LZBaF6bFFBercg1Jz_e10upauYPWL_OSa7N5nVxx-WXz3Gqf4dXD_6y5-fTx2-WX7vrr56vLi-vOMERKNyFrkGVE2hGPFMtplNYwbSnj04gmJvkIuq6Mo34C1FMrR8CWaqsBac7IWXO1405R36o5uY1O9ypqp34VYlopnYozHpQc7MAopwaJgfKRC1lbCyotHwlhglbWhx1rXsYNTAZCSdofQA9PglurVbxTw0AHhGQFvHsApPh9gVzUxmUD3usAcckKy54xwQnhVfr2ifQ2Lqne-VZFKMNooOiPaqXrAC7YWPuaLVRdDBj3A5F8yzr_i6p-E2ycqbmyrtYPDG_2B_094WN2qoDvBCbFnBNYZVzR25evZOcVRmqbUrVLqarhU9uUKlKd-InzEf4_T7_z5KoNK0h7d_FP00-Dc_sE |
| CitedBy_id | crossref_primary_10_5937_jomb0_35933 crossref_primary_10_1177_0961203320904997 crossref_primary_10_3390_jcm11195759 crossref_primary_10_1016_j_kint_2024_09_007 crossref_primary_10_1053_j_ackd_2019_09_001 crossref_primary_10_1155_2020_8855614 crossref_primary_10_1111_jfbc_13476 crossref_primary_10_1371_journal_pone_0275016 crossref_primary_10_1159_000517852 crossref_primary_10_1007_s11255_020_02732_3 crossref_primary_10_1016_j_jtauto_2020_100042 crossref_primary_10_1177_0961203318788167 crossref_primary_10_1038_s41598_024_83057_4 crossref_primary_10_1007_s10067_023_06698_2 crossref_primary_10_34067_KID_0001492022 crossref_primary_10_1080_1744666X_2023_2260098 crossref_primary_10_3390_ijms25020805 crossref_primary_10_1371_journal_pone_0240942 crossref_primary_10_1016_j_trsl_2018_08_002 crossref_primary_10_1155_2020_2768326 crossref_primary_10_1177_0961203319860907 |
| Cites_doi | 10.1016/S0140-6736(05)74811-X 10.1053/j.ajkd.2008.01.020 10.2147/IJNRD.S93866 10.1038/ki.2010.165 10.1038/ki.1984.75 10.1016/j.clim.2014.06.007 10.1136/ard.50.7.490 10.1053/j.ackd.2011.12.001 10.1177/0961203311415560 10.1155/2016/4904502 10.1016/j.cca.2013.07.030 10.1097/01.ASN.0000088027.54400.C6 10.1038/ki.2008.499 10.11622/smedj.2015003 10.1159/000078452 10.4093/dmj.2012.36.4.307 10.1002/art.33485 10.1002/art.1780350606 10.1002/art.22008 10.1177/0961203315600244 10.1093/rheumatology/kep468 10.1177/0961203314550225 10.1006/geno.1997.4896 10.1016/j.kjms.2012.10.004 10.1002/acr.20397 10.1681/ASN.2006070704 10.1016/j.autrev.2005.10.006 10.1002/art.22594 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2017 COPYRIGHT 2017 BioMed Central Ltd. Copyright BioMed Central 2017 |
| Copyright_xml | – notice: The Author(s). 2017 – notice: COPYRIGHT 2017 BioMed Central Ltd. – notice: Copyright BioMed Central 2017 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12882-017-0678-3 |
| DatabaseName | SpringerOpen Free (Free internet resource, activated by CARLI) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database Proquest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Acceso a contenido Full Text - Doaj |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: SpringerOpen Free (Free internet resource, activated by CARLI) url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2369 |
| EndPage | 8 |
| ExternalDocumentID | oai_doaj_org_article_95f56474c08547b789c0f849f7b33684 PMC5545009 A511253977 28778196 10_1186_s12882_017_0678_3 |
| Genre | Multicenter Study Journal Article |
| GeographicLocations | Thailand |
| GeographicLocations_xml | – name: Thailand |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5GY 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABUWG ACGFO ACGFS ACIHN ACPRK ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EJD EMB EMOBN F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 UKHRP W2D WOQ WOW XSB AAYXX ALIPV CITATION -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7QP 7XB 8FK AHSBF AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c603t-d0fc0f639fb1b419db9fc6af467db0d697bea6976702de024f9be1f4afae0a763 |
| IEDL.DBID | M48 |
| ISSN | 1471-2369 |
| IngestDate | Wed Aug 27 01:27:43 EDT 2025 Thu Aug 21 17:40:48 EDT 2025 Thu Sep 04 22:43:24 EDT 2025 Fri Jul 25 04:07:17 EDT 2025 Tue Jun 17 21:47:42 EDT 2025 Tue Jun 10 20:08:24 EDT 2025 Thu Jan 02 23:11:50 EST 2025 Thu Apr 24 22:57:45 EDT 2025 Tue Jul 01 00:48:39 EDT 2025 Sat Sep 06 07:21:48 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | systemic lupus erythematosus (SLE) ROC curve Neutrophil gelatinase-associated lipocalin (NGAL) lupus nephritis (LN) |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c603t-d0fc0f639fb1b419db9fc6af467db0d697bea6976702de024f9be1f4afae0a763 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://doaj.org/article/95f56474c08547b789c0f849f7b33684 |
| PMID | 28778196 |
| PQID | 1934610540 |
| PQPubID | 44769 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_95f56474c08547b789c0f849f7b33684 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5545009 proquest_miscellaneous_1926687337 proquest_journals_1934610540 gale_infotracmisc_A511253977 gale_infotracacademiconefile_A511253977 pubmed_primary_28778196 crossref_citationtrail_10_1186_s12882_017_0678_3 crossref_primary_10_1186_s12882_017_0678_3 springer_journals_10_1186_s12882_017_0678_3 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-08-04 |
| PublicationDateYYYYMMDD | 2017-08-04 |
| PublicationDate_xml | – month: 08 year: 2017 text: 2017-08-04 day: 04 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationSubtitle | BMC series – open, inclusive and trusted |
| PublicationTitle | BMC nephrology |
| PublicationTitleAbbrev | BMC Nephrol |
| PublicationTitleAlternate | BMC Nephrol |
| PublicationYear | 2017 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | HY Lin (678_CR24) 2013; 29 F Sharifipour (678_CR19) 2013; 16 KW Tang (678_CR32) 2015; 56 YG Fang (678_CR21) 2015; 24 M Dall'Era (678_CR30) 2011; 63 JB Cowland (678_CR5) 1997; 45 SS Waikar (678_CR33) 2010; 78 C Bombardier (678_CR13) 1992; 35 A Sirisopha (678_CR10) 2016; 2016 KS Woo (678_CR9) 2012; 36 HI Brunner (678_CR11) 2006; 54 J Mishra (678_CR7) 2005; 365 CC Yang (678_CR27) 2012; 2012 B Satirapoj (678_CR4) 2012; 19 JM Esdaile (678_CR2) 1994; 21 A Samanta (678_CR1) 1991; 50 EA Elewa (678_CR23) 2015; 24 SM Alharazy (678_CR25) 2013; 425 J Mishra (678_CR8) 2004; 24 Y Li (678_CR31) 2006; 5 RD Pawar (678_CR18) 2014; 154 B Satirapoj (678_CR3) 2007; 25 HA Austin III (678_CR14) 1984; 25 D Bolignano (678_CR16) 2008; 52 T Kuwabara (678_CR22) 2009; 75 M Pitashny (678_CR26) 2007; 56 H Durahim Al (678_CR29) 2011; 20 AA Eddy (678_CR15) 2006; 17 J Mishra (678_CR6) 2003; 14 LM Amezcua-Guerra (678_CR28) 2011; 57 T Rubinstein (678_CR20) 2010; 49 B Satirapoj (678_CR12) 2015; 8 RD Pawar (678_CR17) 2012; 64 22950063 - Diabetes Metab J. 2012 Aug;36(4):307-13 27525120 - Int J Nephrol. 2016;2016:4904502 21888025 - Clin Lab. 2011;57(7-8):607-13 24171081 - Iran J Basic Med Sci. 2013 Sep;16(9):1011-5 17530720 - Arthritis Rheum. 2007 Jun;56(6):1894-903 24971701 - Clin Immunol. 2014 Sep;154(1):49-65 21080348 - Arthritis Care Res (Hoboken). 2011 Mar;63(3):351-7 9339356 - Genomics. 1997 Oct 1;45(1):17-23 16890891 - Autoimmun Rev. 2006 Jul;5(6):383-8 17035605 - J Am Soc Nephrol. 2006 Nov;17(11):2964-6 21813588 - Lupus. 2011 Oct;20(12):1329-35 1877855 - Ann Rheum Dis. 1991 Jul;50(7):490-2 18725016 - Am J Kidney Dis. 2008 Sep;52(3):595-605 14514731 - J Am Soc Nephrol. 2003 Oct;14 (10 ):2534-43 22449346 - Adv Chronic Kidney Dis. 2012 Mar;19(2):93-100 25640093 - Singapore Med J. 2015 Jan;56(1):7-10 23954775 - Clin Chim Acta. 2013 Oct 21;425:163-8 20144927 - Rheumatology (Oxford). 2010 May;49(5):960-71 20555318 - Kidney Int. 2010 Sep;78(5):486-94 6482173 - Kidney Int. 1984 Apr;25(4):689-95 1599520 - Arthritis Rheum. 1992 Jun;35(6):630-40 26314302 - Lupus. 2015 Dec;24(14 ):1529-39 25199807 - Lupus. 2015 Feb;24(2):138-46 22500106 - J Biomed Biotechnol. 2012;2012:759313 23684135 - Kaohsiung J Med Sci. 2013 Jun;29(6):304-11 7869308 - J Rheumatol. 1994 Nov;21(11):2046-51 26527894 - Int J Nephrol Renovasc Dis. 2015 Oct 21;8:145-50 19148153 - Kidney Int. 2009 Feb;75(3):285-94 15811456 - Lancet. 2005 Apr 2-8;365(9466):1231-8 17891918 - Asian Pac J Allergy Immunol. 2007 Mar;25(1):17-25 15148457 - Am J Nephrol. 2004 May-Jun;24(3):307-15 22083497 - Arthritis Rheum. 2012 May;64(5):1620-31 16868980 - Arthritis Rheum. 2006 Aug;54(8):2577-84 |
| References_xml | – volume: 365 start-page: 1231 issue: 9466 year: 2005 ident: 678_CR7 publication-title: Lancet doi: 10.1016/S0140-6736(05)74811-X – volume: 52 start-page: 595 issue: 3 year: 2008 ident: 678_CR16 publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2008.01.020 – volume: 8 start-page: 145 year: 2015 ident: 678_CR12 publication-title: Int J Nephrol Renovasc Dis doi: 10.2147/IJNRD.S93866 – volume: 78 start-page: 486 issue: 5 year: 2010 ident: 678_CR33 publication-title: Kidney Int doi: 10.1038/ki.2010.165 – volume: 25 start-page: 689 issue: 4 year: 1984 ident: 678_CR14 publication-title: Kidney Int doi: 10.1038/ki.1984.75 – volume: 154 start-page: 49 issue: 1 year: 2014 ident: 678_CR18 publication-title: Clin Immunol doi: 10.1016/j.clim.2014.06.007 – volume: 50 start-page: 490 issue: 7 year: 1991 ident: 678_CR1 publication-title: Ann Rheum Dis doi: 10.1136/ard.50.7.490 – volume: 19 start-page: 93 issue: 2 year: 2012 ident: 678_CR4 publication-title: Adv Chronic Kidney Dis doi: 10.1053/j.ackd.2011.12.001 – volume: 20 start-page: 1329 issue: 12 year: 2011 ident: 678_CR29 publication-title: Lupus doi: 10.1177/0961203311415560 – volume: 21 start-page: 2046 issue: 11 year: 1994 ident: 678_CR2 publication-title: J Rheumatol – volume: 2016 start-page: 4904502 year: 2016 ident: 678_CR10 publication-title: Int J Nephrol doi: 10.1155/2016/4904502 – volume: 425 start-page: 163 year: 2013 ident: 678_CR25 publication-title: Clin Chim Acta doi: 10.1016/j.cca.2013.07.030 – volume: 14 start-page: 2534 issue: 10 year: 2003 ident: 678_CR6 publication-title: J Am Soc Nephrol doi: 10.1097/01.ASN.0000088027.54400.C6 – volume: 75 start-page: 285 issue: 3 year: 2009 ident: 678_CR22 publication-title: Kidney Int doi: 10.1038/ki.2008.499 – volume: 56 start-page: 7 issue: 1 year: 2015 ident: 678_CR32 publication-title: Singap Med J doi: 10.11622/smedj.2015003 – volume: 24 start-page: 307 issue: 3 year: 2004 ident: 678_CR8 publication-title: Am J Nephrol doi: 10.1159/000078452 – volume: 36 start-page: 307 issue: 4 year: 2012 ident: 678_CR9 publication-title: Diabetes Metab J doi: 10.4093/dmj.2012.36.4.307 – volume: 64 start-page: 1620 issue: 5 year: 2012 ident: 678_CR17 publication-title: Arthritis Rheum doi: 10.1002/art.33485 – volume: 35 start-page: 630 issue: 6 year: 1992 ident: 678_CR13 publication-title: Arthritis Rheum doi: 10.1002/art.1780350606 – volume: 54 start-page: 2577 issue: 8 year: 2006 ident: 678_CR11 publication-title: Arthritis Rheum doi: 10.1002/art.22008 – volume: 2012 start-page: 759313 year: 2012 ident: 678_CR27 publication-title: J Biomed Biotechnol – volume: 24 start-page: 1529 issue: 14 year: 2015 ident: 678_CR21 publication-title: Lupus doi: 10.1177/0961203315600244 – volume: 49 start-page: 960 issue: 5 year: 2010 ident: 678_CR20 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/kep468 – volume: 24 start-page: 138 issue: 2 year: 2015 ident: 678_CR23 publication-title: Lupus doi: 10.1177/0961203314550225 – volume: 45 start-page: 17 issue: 1 year: 1997 ident: 678_CR5 publication-title: Genomics doi: 10.1006/geno.1997.4896 – volume: 29 start-page: 304 issue: 6 year: 2013 ident: 678_CR24 publication-title: Kaohsiung J Med Sci doi: 10.1016/j.kjms.2012.10.004 – volume: 57 start-page: 607 issue: 7–8 year: 2011 ident: 678_CR28 publication-title: Clin Lab – volume: 63 start-page: 351 issue: 3 year: 2011 ident: 678_CR30 publication-title: Arthritis Care Res (Hoboken) doi: 10.1002/acr.20397 – volume: 17 start-page: 2964 issue: 11 year: 2006 ident: 678_CR15 publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2006070704 – volume: 25 start-page: 17 issue: 1 year: 2007 ident: 678_CR3 publication-title: Asian Pac J Allergy Immunol – volume: 16 start-page: 1011 issue: 9 year: 2013 ident: 678_CR19 publication-title: Iran J Basic Med Sci – volume: 5 start-page: 383 issue: 6 year: 2006 ident: 678_CR31 publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2005.10.006 – volume: 56 start-page: 1894 issue: 6 year: 2007 ident: 678_CR26 publication-title: Arthritis Rheum doi: 10.1002/art.22594 – reference: 26527894 - Int J Nephrol Renovasc Dis. 2015 Oct 21;8:145-50 – reference: 23684135 - Kaohsiung J Med Sci. 2013 Jun;29(6):304-11 – reference: 22500106 - J Biomed Biotechnol. 2012;2012:759313 – reference: 25640093 - Singapore Med J. 2015 Jan;56(1):7-10 – reference: 14514731 - J Am Soc Nephrol. 2003 Oct;14 (10 ):2534-43 – reference: 20144927 - Rheumatology (Oxford). 2010 May;49(5):960-71 – reference: 17035605 - J Am Soc Nephrol. 2006 Nov;17(11):2964-6 – reference: 24971701 - Clin Immunol. 2014 Sep;154(1):49-65 – reference: 20555318 - Kidney Int. 2010 Sep;78(5):486-94 – reference: 21888025 - Clin Lab. 2011;57(7-8):607-13 – reference: 15811456 - Lancet. 2005 Apr 2-8;365(9466):1231-8 – reference: 23954775 - Clin Chim Acta. 2013 Oct 21;425:163-8 – reference: 6482173 - Kidney Int. 1984 Apr;25(4):689-95 – reference: 19148153 - Kidney Int. 2009 Feb;75(3):285-94 – reference: 9339356 - Genomics. 1997 Oct 1;45(1):17-23 – reference: 1877855 - Ann Rheum Dis. 1991 Jul;50(7):490-2 – reference: 1599520 - Arthritis Rheum. 1992 Jun;35(6):630-40 – reference: 27525120 - Int J Nephrol. 2016;2016:4904502 – reference: 7869308 - J Rheumatol. 1994 Nov;21(11):2046-51 – reference: 25199807 - Lupus. 2015 Feb;24(2):138-46 – reference: 16868980 - Arthritis Rheum. 2006 Aug;54(8):2577-84 – reference: 26314302 - Lupus. 2015 Dec;24(14 ):1529-39 – reference: 17891918 - Asian Pac J Allergy Immunol. 2007 Mar;25(1):17-25 – reference: 22950063 - Diabetes Metab J. 2012 Aug;36(4):307-13 – reference: 22449346 - Adv Chronic Kidney Dis. 2012 Mar;19(2):93-100 – reference: 17530720 - Arthritis Rheum. 2007 Jun;56(6):1894-903 – reference: 22083497 - Arthritis Rheum. 2012 May;64(5):1620-31 – reference: 16890891 - Autoimmun Rev. 2006 Jul;5(6):383-8 – reference: 18725016 - Am J Kidney Dis. 2008 Sep;52(3):595-605 – reference: 21080348 - Arthritis Care Res (Hoboken). 2011 Mar;63(3):351-7 – reference: 24171081 - Iran J Basic Med Sci. 2013 Sep;16(9):1011-5 – reference: 15148457 - Am J Nephrol. 2004 May-Jun;24(3):307-15 – reference: 21813588 - Lupus. 2011 Oct;20(12):1329-35 |
| SSID | ssj0017840 |
| Score | 2.2347972 |
| Snippet | Background
Tubulointerstitial injury is important to predict the progression of lupus nephritis (LN). Urine neutrophil gelatinase-associated lipocalin (NGAL)... Tubulointerstitial injury is important to predict the progression of lupus nephritis (LN). Urine neutrophil gelatinase-associated lipocalin (NGAL) has been... Background Tubulointerstitial injury is important to predict the progression of lupus nephritis (LN). Urine neutrophil gelatinase-associated lipocalin (NGAL)... Abstract Background Tubulointerstitial injury is important to predict the progression of lupus nephritis (LN). Urine neutrophil gelatinase-associated lipocalin... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 263 |
| SubjectTerms | Adult Analysis Arthritis Biomarkers Biomarkers - urine Biopsy Blood pressure Care and treatment Clinical Research Complement component C3 Creatinine Enzyme-linked immunosorbent assay Enzymes Female Follow-Up Studies Gelatinase Genetic aspects Glomerular filtration rate Health risk assessment Humans Induction Chemotherapy - trends Induction therapy Internal Medicine Kidney diseases Kidneys Laboratories Lipocalin Lipocalin-2 - urine Lupus Lupus nephritis lupus nephritis (LN) Lupus Nephritis - diagnosis Lupus Nephritis - drug therapy Lupus Nephritis - urine Male Medicine Medicine & Public Health Mortality Nephritis Nephrology Neutrophil gelatinase-associated lipocalin (NGAL) Neutrophils Patients Physiological aspects Predictive Value of Tests Prognosis Prospective Studies Proteins Proteinuria Research Article Rheumatology ROC curve Rodents Statistical analysis systemic lupus erythematosus (SLE) Transport proteins Urine Young Adult |
| SummonAdditionalLinks | – databaseName: Acceso a contenido Full Text - Doaj dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9QwFA-yB_EifltdJYIgKGXTSZqkx1VcFmE9ObC30Hy5A0Nn6LQHwT_e99LMMF1RL156aJI2yXt57_fIyy-EvI2u8uBXeanqipfCVa5snI2lqKyIAGiFshgoXn2Vl0vx5bq-PrrqC3PCJnrgaeLOmjrWUijhABtAQ6Ubx6IWTVSWc6kTEyhr2D6YyvsHCuKWvIdZaXm2AyusMQUBU70wH2DmhRJZ_-8m-cgn3c6XvLVpmnzRxQNyP4NIej51_iG5E7pH5O5V3iZ_TH4u8Uwf7cI49JvtzWpNv6ectw5cVtlmgQRP16sturJVR4cN3fbYfqB9wG_3U-5soOkScQqR-0QzS6cDWz_gDW2TraTrcTvu4GegFkiQ9IQsLz5_-3RZ5msWSicZH0rPIkwpIJVoQUBV420TnWwjmFBvmZeNsqGFp1Rs4QP49NjYUEXRxjawFuzTU3LSbbrwnFDmo160IngOT6fqlsnIag-isoLHoAvC9tNuXOYgx6sw1ibFIlqaSVIGJGVQUoYX5P2hyXYi4Phb5Y8oy0NF5M5OL0CjTNYo8y-NKsg71ASDKxw659p8UAGGiFxZ5hwxao3AuSCns5qwMt28eK9LJluGnQHAjBT3AJQL8uZQjC0x260LmxHrAGzSinP4xLNJ9Q5DgghXAYqTBVEzpZyNeV7SrW4SbzggxxogdUE-7NX3qFt_mtIX_2NKX5J7i7T4dMnEKTkZ-jG8AjA32Ndp3f4CXClFwQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gvgifl_PUyIIglIu3aZJ-ySneBzC-eTCvoXm625haWu3fRD8428mza7XE--lD82kTTqTmd80kxlC3nuTWbCreSqLLE-5yUxaGe1TnmnuAdByqdFRvPghzpf8-6pYxR9u2xhWudOJQVHb1uA_8hMAGpgaHADG5-5XilWjcHc1ltC4Tx5kQIClG-Rq73BlEryXuJOZleJkC7q4xEAEDPjCqICZLQop-_9VzDcs0-2oyVtbp8EinT0hjyOUpKcT75-Se655Rh5exM3y5-TPEk_20caNQ992V-sNvQyRbw0YrrSObHGWbtYdGrR1Q4eWdj32H2jv8Nn9FEHraCglTsF_n5LN0unY1m-4Q-ugMelm7MYtvAyEA9MkvSDLs28_v56nsdhCagTLh9Qyb5gHvOI1sCmrrK68EbUHRWo1s6KS2tVwFZItrAPL7ivtMs9rXztWg5Z6SQ6atnGHhDLry0XNnc3hamRRM-FZYaXONc-9KxPCdp9dmZiJHAtibFTwSEqhJk4p4JRCTqk8IR_3XbopDcddxF-Ql3tCzKAdbrT9pYoLUlWFLwSX3ADmBIGUZQXTL3nlYZi5KHlCPqAkKFznMDhTx-MKMEXMmKVOEakWCJ8TcjyjhPVp5s07WVJRP2zVX2lOyLt9M_bEmLfGtSPSAHgqZZ7DI15NorefEvi5ErCcSIicCeVszvOWZn0VsocDfiwAWCfk0058bwzrf5_06O5JvCaPFmFZlSnjx-Rg6Ef3BsDaoN-GFXkNFBE-pQ priority: 102 providerName: ProQuest – databaseName: SpringerOpen Free (Free internet resource, activated by CARLI) dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEA96gvgifls9JYIgKMV0kybp47l4HML55MK9hSZNvIWlW7rtg-Af70yaXbbnB_jSh2aSJp3JzG-YyYSQt8EVDdhVnquy4LlwhcsrZ0MuCisCAFqhLDqKl1_lxUp8uSqvUrFoPAtzHL8vtPy4A_2pMXkAk7Qwkn-b3IFRGQrzUi4PAQMFjkoKWv6x28zsxOr8v-vgIyN0M0HyRpQ0Gp_zB-R-Qo30bGLzQ3LLt4_I3csUF39Mfq7wEB9t_Tj02-56vaHfY5JbCzYqrxMHfEM36w5t17qlw5Z2PfYfaO9x7H5KlvU03hpOwVWf6srS6YTWD3hD66gc6Wbsxh18DOQAKyI9Iavzz9-WF3m6VyF3kvEhb1hwLAA0CRY4UlSNrYKTdQCd2VjWyEpZX8NTKrZoPBjxUFlfBFGH2rMaFNJTctJuW_-cUNYEvaiFbzg8nSprJgMrG2W5FTx4nRG2_-3GpaLjePfFxkTnQ0szccoApwxyyvCMvD906aaKG_8i_oS8PBBisez4AmTIpL1nqjKUUijhAF6C7CldwfK1qAJMk0stMvIOJcHglobJuTqdTIAlYnEsc4agtESknJHTGSVsRTdv3suSSapgZwAhY017QMYZeXNoxp6Y3tb67Yg0gJO04hyGeDaJ3mFJ4NIqgG0yI2omlLM1z1va9XUsFA5QsQQMnZEPe_E9mtbffumL_6J-Se4t4i7TOROn5GToR_8KYNpgX8cN-gsaXTdC priority: 102 providerName: Springer Nature |
| Title | Urine neutrophil gelatinase-associated lipocalin to predict renal response after induction therapy in active lupus nephritis |
| URI | https://link.springer.com/article/10.1186/s12882-017-0678-3 https://www.ncbi.nlm.nih.gov/pubmed/28778196 https://www.proquest.com/docview/1934610540 https://www.proquest.com/docview/1926687337 https://pubmed.ncbi.nlm.nih.gov/PMC5545009 https://doaj.org/article/95f56474c08547b789c0f849f7b33684 |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ba9swFBa9wNjL2H3euqDBYLDhTY5kSX4YIw0tJdAytgX6JmxZagPByRwHVtiP3zmyk9VdN_bigHWxpHP7lHN0RMhrb5MS7CqPVZrwWNjExpktfCySQngAtEIVuFE8PZMnUzE5T893yOZ6q24BV7du7fA-qWk9f__j-9UnEPiPQeC1_LACHasxwAADudDbv0v2g7sII_nEb6eC0u35SNDH8ZDLrHNy3tpFz0yFbP5_6uxrRutmQOUNr2owVsf3yb0OZdJRyxYPyI6rHpI7p50f_RH5OcVDf7Ry66ZeLC9nc3oRguIqsGlx3lHMlXQ-W6Ktm1W0WdBlje0bWjvsu26Dax0Nt4xT2Nq3eWhpe6LrCt7QPChTOl8v1yv4GPANZlB6TKbHR9_GJ3F3D0NsJeNNXDJvmQco4wugYJKVReatzD3o2LJgpcxU4XJ4SsWGpQOj77PCJV7kPncsBwX2hOxVi8o9I5SVXg9z4UoOT6vSnEnP0lIVvBDcOx0Rtll2Y7sk5XhXxtyEzYqWpqWUAUoZpJThEXm7bbJsM3T8q_Ih0nJbEZNrhxeL-sJ0smqy1KdSKGEBjgKvKp3B9LXIPAyTSy0i8gY5wSBTwuBs3p1kgCliMi0zQhCbIrKOyEGvJoiu7RdveMlsON8AosYc-ICkI_JqW4wtMRyucos11gFcpRXn0MXTlvW2U4ItsAKYJyOiekzZm3O_pJpdhsTiAC1TwNwRebdh32vD-tuSPv-PUb4gd4dBtnTMxAHZa-q1ewlgrikGZFedqwHZH40mXyfwe3h09vkLvB3L8SD8QTIIQvwLZsxLiw |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3da9RAEF_qFdSX4repVVdQBCU0uWyyyUORVluutneI9KBv22Q_2oMjibkcUvBv829zJtmcTcW-9SUP2Y_sZmZnfrM7O0PIWyN9BXo1cHnoBy6TvnQTmRmX-RkzAGgZz9BQHE-i0ZR9PQ1P18jv7i4MulV2MrER1KqQuEe-DUADQ4MDwPhU_nAxaxSernYpNFKbWkHtNCHG7MWOI335E0y4xc7hF6D3u-HwYP_k88i1WQZcGXlB7SrPSM-AojYZjM9PVJYYGaUGJIjKPBUlPNMpPCPuDZUGlWaSTPuGpSbVXgrLE_q9Q9YZbqAMyPre_uTb99U5Bgf7yZ6l-nG0vQBtEKMrBLqcoV9CTxs2SQP-VQ1XdON1v81rh7eNTjx4QDYsmKW7Lfc9JGs6f0Tuju1x_WPya4p3C2mul3VVlBezOT1vfO9yUJ1uahlDKzqflahSZzmtC1pW2L6mlca-q9aHV9MmmTmd5aoNd0vbi2OX8Iamjcym82W5XMDHgD0xUNMTMr0VQjwlg7zI9XNCPWXiYcq0CuApeZh6kfFCxbMgY4HRsUO87rcLaWOhY0qOuWhsojgSLaUEUEogpUTgkA-rJmUbCOSmyntIy1VFjOHdvCiqc2FFgkhCE0aMMwmoF5YEjxOYfswSA8MMopg55D1ygkBJA4OTqb0wAVPEmF1iF7FyiADeIVu9miAhZL-44yVhJdRC_F1PDnmzKsaW6HWX62KJdQC-xTwIoItnLeutpgSWNgc0GTmE95iyN-d-ST67aOKXA4INAdo75GPHvleG9b9funnzJF6Te6OT8bE4PpwcvSD3h80Si12PbZFBXS31S4COdfbKrk9Kzm5bJPwBF02ELw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bi9QwFA66C4sv4t3qqhEEQSmbTtMkfRwvyzq6i6AD-xaa2-7A0CmdzoPgj_ecNjNs1wv40ocmaZOc23c4JyeEvAo2c2BX81QWWZ5ym9m0tCakPDM8AKDl0qCjeHomTuZ8dl6cx3tO19ts921IcjjTgFWa6u6ocWEQcSWO1qBVFaYUYOoWxvdvkn1VlCV4X_vT6ezbbBdIkODAxGDmHweOzFFftf933XzFOF1PnLwWPe2N0vEdcjuiSTodyH-X3PD1PXJwGuPl98nPOR7uo7XfdO2quVws6UWf_FaD7UqrSBnv6HLRoE1b1LRb0abF8R1tPX67HZJoPe1vE6fgwg_1ZulwcusHvKFVrzTpctNs1vAz4A-slPSAzI8_fn9_ksb7FlIrWN6ljgXLAkCWYIBSWelMGayoAuhSZ5gTpTS-gqeQbOI8GPdQGp8FXoXKswoU1UOyV69q_5hQ5oKaVNy7HJ5WFhUTgRVOmtzwPHiVELbddm1jMXK8E2Ope6dECT1QSgOlNFJK5wl5sxvSDJU4_tX5HdJy1xGLaPcvVu2FjjKpyyIUgktuAXYCT0pVwvIVLwNMMxeKJ-Q1coJGUYfJ2SqeWIAlYtEsPUWwWiCCTsjhqCeIqB03b3lJRxWx1oCcsdY9IOaEvNw140hMe6v9aoN9AD8pmefwiUcD6-2WBK6uBDgnEiJHTDla87ilXlz2BcQBQhaArRPydsu-V6b1ty198l-9X5CDrx-O9ZdPZ5-fkluTXuBUyvgh2evajX8GSK4zz6O0_gJWEkPv |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Urine+neutrophil+gelatinase-associated+lipocalin+to+predict+renal+response+after+induction+therapy+in+active+lupus+nephritis&rft.jtitle=BMC+nephrology&rft.au=Satirapoj%2C+Bancha&rft.au=Kitiyakara%2C+Chagriya&rft.au=Leelahavanichkul%2C+Asada&rft.au=Avihingsanon%2C+Yingyos&rft.date=2017-08-04&rft.issn=1471-2369&rft.eissn=1471-2369&rft.volume=18&rft.issue=1&rft.spage=263&rft_id=info:doi/10.1186%2Fs12882-017-0678-3&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2369&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2369&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2369&client=summon |